OncoSec Medical (NASDAQ:ONCS) had its price target hoisted by Piper Jaffray Companies to $5.00 in a research note released on Tuesday, The Fly reports. The brokerage currently has an overweight rating on the biotechnology company’s stock. Piper Jaffray Companies also issued estimates for OncoSec Medical’s Q4 2018 earnings at ($0.18) EPS, FY2018 earnings at ($0.86) EPS, Q1 2019 earnings at ($0.19) EPS, Q2 2019 earnings at ($0.20) EPS, Q3 2019 earnings at ($0.20) EPS, Q4 2019 earnings at ($0.21) EPS and FY2019 earnings at ($0.81) EPS.

ONCS has been the topic of several other reports. Dawson James reaffirmed a buy rating on shares of OncoSec Medical in a report on Monday, July 16th. Maxim Group set a $5.00 price objective on shares of OncoSec Medical and gave the stock a buy rating in a research report on Monday, April 16th. HC Wainwright set a $4.00 price objective on shares of OncoSec Medical and gave the stock a buy rating in a research report on Tuesday, August 7th. Finally, ValuEngine upgraded shares of OncoSec Medical from a sell rating to a hold rating in a research report on Wednesday, May 2nd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $4.67.

NASDAQ:ONCS traded down $0.05 during mid-day trading on Tuesday, hitting $1.53. The company’s stock had a trading volume of 5,895 shares, compared to its average volume of 892,838. OncoSec Medical has a 1 year low of $0.88 and a 1 year high of $2.95. The firm has a market cap of $79.04 million, a price-to-earnings ratio of -1.46 and a beta of 2.75.

OncoSec Medical (NASDAQ:ONCS) last posted its quarterly earnings results on Wednesday, June 13th. The biotechnology company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.04). research analysts predict that OncoSec Medical will post -0.81 EPS for the current year.

In other OncoSec Medical news, CFO Richard B. Slansky sold 84,984 shares of the company’s stock in a transaction dated Thursday, July 5th. The shares were sold at an average price of $1.39, for a total value of $118,127.76. Following the completion of the transaction, the chief financial officer now owns 255,000 shares in the company, valued at $354,450. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Punit Dhillon sold 55,585 shares of the company’s stock in a transaction dated Wednesday, June 20th. The stock was sold at an average price of $1.42, for a total transaction of $78,930.70. Following the completion of the transaction, the director now owns 355,702 shares of the company’s stock, valued at approximately $505,096.84. The disclosure for this sale can be found here. In the last quarter, insiders sold 300,106 shares of company stock valued at $419,658. Insiders own 5.50% of the company’s stock.

Several institutional investors have recently modified their holdings of the business. Millennium Management LLC raised its position in shares of OncoSec Medical by 19.5% in the second quarter. Millennium Management LLC now owns 1,195,315 shares of the biotechnology company’s stock worth $1,650,000 after acquiring an additional 194,739 shares during the period. Nexthera Capital LP raised its position in shares of OncoSec Medical by 26.6% in the second quarter. Nexthera Capital LP now owns 2,614,297 shares of the biotechnology company’s stock worth $3,608,000 after acquiring an additional 550,000 shares during the period. DRW Securities LLC raised its position in shares of OncoSec Medical by 157.1% in the second quarter. DRW Securities LLC now owns 180,000 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 110,000 shares during the period. BlackRock Inc. raised its position in shares of OncoSec Medical by 1,303.5% in the second quarter. BlackRock Inc. now owns 238,940 shares of the biotechnology company’s stock worth $330,000 after acquiring an additional 221,916 shares during the period. Finally, Point72 Asset Management L.P. raised its position in shares of OncoSec Medical by 47.5% in the first quarter. Point72 Asset Management L.P. now owns 3,215,000 shares of the biotechnology company’s stock worth $6,044,000 after acquiring an additional 1,035,000 shares during the period. Institutional investors and hedge funds own 26.01% of the company’s stock.

About OncoSec Medical

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.

Featured Story: What is a Leveraged Buyout (LBO)?

The Fly

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.